Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57 GBX | +2.70% | +8.57% | -32.14% |
04-17 | AIM WINNERS & LOSERS: Inspecs confident but Scirocco eyes AIM exit | AN |
04-17 | Inspecs hails "encouraging" recent trading after tepid start to 2024 | AN |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.4 for the 2024 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.14% | 72.18M | C- | ||
+11.95% | 98.12B | B | ||
-6.10% | 17.66B | B- | ||
-20.02% | 2.24B | D+ | ||
-8.37% | 1.54B | C+ | ||
+29.63% | 1.23B | - | ||
-35.36% | 735M | B- | ||
-35.62% | 747M | - | ||
-13.36% | 623M | - | ||
+24.04% | 494M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SPEC Stock
- Ratings INSPECS Group plc